Why payout is better for R&D investment in India?
Indian drug firms like Ranbaxy, Reddy Labs debunked the notion that new molecule discovery needs a billion dollar . This is not an isolated event is proved by research carried out at Booz Allen Hamilton, which concluded that new players in India and China with a set of different innovation effectiveness curves , need lesser resources to produce similar results than long established MNCs based in Europe, USA. The laws of diminishing returns had already set in for those MNC firms.
Read: http://www.strategy-business.com/media/file/rr00007.pdf
No comments:
Post a Comment